Evgen Pharma plc announced that Non-Executive Chair, Barry Clare, will be retiring as Chairman of the Board and a director of the Company at the next board meeting on 21 September 2023. The role of Chair will be passed to Dr Susan Foden, currently Senior Non-executive Director, on an interim basis. Barry was appointed Non-Executive Chair at the foundation of Evgen in 2007 and has overseen the evolution of the Company and board, including the IPO on AIM in October 2015 and more recently the partnership with Stalicla SA exploring the potential therapeutic benefit of sulforaphane in autism.

Susan Foden, the incoming interim Chair, has considerable experience as a non-executive director working with public and private companies. Susan has held NED roles at Vectura plc, BerGenBio AS, BTG plc and, recently served as Chair of Neurocentrx Ltd. She is currently Non-executive Deputy Chair of Australian biotech QBiotics, an Investment Committee member of CD3, the drug discovery initiative between the European Investment Fund and the University of Leuven in Belgium and a Trustee of the Roslin Foundation in Edinburgh, UK.